Abstract

An oral preparation for treating cell proliferation diseases. The oral preparation comprises hydroxylpropoxyl-β-cyclodextrin and an active component. The active component is KX2-361 or a medicinal salt thereof, and KX2-361 is represented by formula 1. By mixing hydroxylpropoxyl-ydcyclodextrin with KX2-361 or the medicinal salt thereof, an inclusion complex is formed, the solubility of the poorly-soluble drug KX2-361 is greatly improved, and accordingly the drug is prepared into an oral preparation. The oral preparation has good stability, high safety, good absorbability, high bioavailability and economical cost.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/20 - Pills, lozenges or tablets
• A61P 35/00 - Antineoplastic agents
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

A pharmaceutical composition comprises an active component KX2-361 represented by formula 1 or a medicinal salt thereof and hydroxylpropoxyl-β-cyclodextrin. An inclusion compound is formed by KX2-361 or the medicinal salt thereof and hydroxylpropoxyl-β-cyclodextrin, and the solubility of the poorly-soluble drug KX2-361 is improved. The pharmaceutical composition can be prepared into an intravenous preparation and an oral preparation.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 9/08 - Solutions
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 9/20 - Pills, lozenges or tablets
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 35/00 - Antineoplastic agents

Abstract

A pharmaceutical composition comprises an active component KX2-361 represented by formula 1 or a medicinal salt thereof and hydroxylpropoxyl-β-cyclodextrin. An inclusion compound is formed by KX2-361 or the medicinal salt thereof and hydroxylpropoxyl-β-cyclodextrin, and the solubility of the poorly-soluble drug KX2-361 is improved. The pharmaceutical composition can be prepared into an intravenous preparation and an oral preparation.

IPC Classes  ?

• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 9/08 - Solutions
• A61K 9/20 - Pills, lozenges or tablets
• A61P 35/00 - Antineoplastic agents

Abstract

An oral preparation for treating cell proliferation diseases. The oral preparation comprises hydroxylpropoxyl-β-cyclodextrin and an active component. The active component is KX2-361 or a medicinal salt thereof, and KX2-361 is represented by formula 1. By mixing hydroxylpropoxyl-β-cyclodextrin with KX2-361 or the medicinal salt thereof, an inclusion compound is formed, the solubility of the poorly-soluble drug KX2-361 is greatly improved, and accordingly the drug is prepared into an oral preparation. The oral preparation has good stability, high safety, good absorbability, high bioavailability and economical cost.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 35/00 - Antineoplastic agents

Abstract

A liquid packaging bag (10), comprising a bag body (100), a bag neck (200) and a grasping member (300). The bag body has a bottom portion and a top portion, and an accommodation cavity (110) for accommodating a liquid. The bag neck is connected to the top portion of the bag body. The bag neck is provided with a tube (210) for providing a liquid flow, the tube communicating with the accommodation cavity. The bag neck has a notch formed for tearing open the bag neck and opening an easy-tear hole of the tube. The grasping member is connected to the bag body. The liquid packaging bag is easily torn open and the liquid in the bag does not readily spill out.

IPC Classes  ?

• B65D 30/10 - Sacks, bags or like containers characterised by shape or construction
• B65D 33/00 - Details of, or accessories for, sacks or bags
• B65D 33/16 - End- or aperture-closing arrangements or devices
• B65D 77/32 - Tearing-strings or like flexible elements

Abstract

A liquid packaging bottle, comprising a bottle body, a sucking tube, a first twist opening member and second twist opening member. The bottle body has an accommodation cavity for accommodating liquid. A first opening and second opening are provided on the bottle body. A dimension of the first opening is larger than that of the second opening. The first opening and second opening each communicate with the accommodation cavity. The sucking tube is disposed within the accommodation cavity and is connected to the accommodation cavity inner wall. One end of the sucking tube communicates with the first opening, and another end is disposed at the bottom of the accommodation cavity. The sucking tube is adhered to the accommodation cavity inner wall. The first twist opening member is connected to the bottle body and seals the first opening. When the first twist opening member separates from the bottle body, the first opening opens. The second twist opening member is connected to bottle body, and seals the second opening. When the second twist opening member separates from the bottle body, the second opening opens. The liquid packaging bottle thus maintains the seal of the liquid inside the bottle, and prevents external contaminants from entering the bottle.

IPC Classes  ?

• B65D 23/00 - Details of bottles or jars not otherwise provided for

Abstract

Provided are a T cell receptor (TCR) and a molecule thereof fused with a therapeutic agent. The binding affinity of the TCR with respect to SLLMWITQC-HLA A2 complex is at least twice of that of a wild-type TCR. The TCR either can be used independently or can be used jointly with the therapeutic agent.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 35/74 - Bacteria
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• A61P 35/00 - Antineoplastic agents

Abstract

Provided is a high-stability T cell receptor (TCR). The TCR comprises (i) the whole or a part of TCRα chain except a transmembrane domain thereof, and (ii) the whole or a part of TCRβ chain except a transmembrane domain thereof, both the (i) and the (ii) comprising a functional variable domain and at least a part of a constant domain of a TCR chain. An artificial interchain disulfide bond links the constant domains of the TCRα and β chains, and a Tm value of the T cell receptor is greater than or equal to 45ºC.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 35/00 - Antineoplastic agents
• A61P 31/12 - Antivirals
• A61P 37/02 - Immunomodulators

Abstract

Provided is a T cell receptor(TCR), combining with KLVALGINAV-HLA-A 2 compound and comprising a TCR α variable domain and/or TCR β variable domain. Also provided is a fusion of a TCR and a therapeutic agent. The TCR can be used separately, and in combination with the therapeutic agent, for target presenting of HCV infection cells of a KLVALGINAV-HLA-A 2 compound.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• C07K 19/00 - Hybrid peptides
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 35/00 - Antineoplastic agents
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention provides a high-stability T-cell receptor, a hydrophobic core region of said T-cell receptor having undergone a mutation, leading to the increased stability thereof. The present invention additionally provides a preparation method and an application of the T-cell receptor.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 31/12 - Antivirals
• A61P 35/00 - Antineoplastic agents
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection